Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MNKD $0.55 0.0700 +14.58%
CASC $5.50 0.5300 +10.66%
BLCM $18.72 1.7400 +10.25%
SYRS $15.47 1.3900 +9.87%
CTIC $0.49 0.0430 +9.73%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TRIL $6.70 -0.5000 -6.94%
MRTX $5.05 -0.2000 -3.81%
BPMC $27.01 -0.9900 -3.54%
RXDX $5.95 -0.2000 -3.25%
LBIO $6.00 -0.2000 -3.23%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Over 130,000 Patients A Year Are Not Receiving Vital NHS Cancer Care On Time

(The Guardian [UK]) Nov 6, 2016 - More than 130,000 patients a year are not receiving vital NHS cancer care on time because hospitals are struggling to look after the growing number of people suspected of having the disease.
read article 

GeoVax and ViaMune to Collaborate on Cancer Immunotherapy Program

(GeoVax) Nov 7, 2016 - GeoVax Labs, Inc. announced today its collaboration with ViaMune, Inc. for the co-development of each company's cancer immunotherapy programs.
read corporate press release 

FDA Approves Roche's VENTANA ALK (D5F3) CDx Assay for Use on the VENTANA BenchMark ULTRA System

(StreetInsider) Nov 7, 2016 - Roche announced today that the U.S. Food and Drug Administration (FDA) has approved the VENTANA ALK (D5F3) CDx Assay1 for use on the VENTANA BenchMark ULTRA automated slide stainer.
read article 

Orphan Status for AbbVie’s PARP Inhibitor

(PharmaTimes [UK]) Nov 7, 2016 - AbbVie's experimental lung cancer drug veliparib has picked up Orphan Drug status in the US, opening the door to potential tax credits, waived fees, protocol assistance and exclusivity benefits.
read article 

McKesson Specialty Health Hosts 2016 Onmark Fall Leadership Summit For Community-Based Oncology Practices

(McKesson) Nov 7, 2016 - Attendees gained valuable insight into preparing their practices for value-based care.
read corporate press release 

Judging Cancer Drugs by Clinical, Not Statistical, Measures

(Medscape Medical News) Nov 4, 2016 - A new study of 277 cancer drug clinical trials found that even when drugs provide a statistically significant benefit, they usually don't provide a clinically significant benefit; time for a new approach to approvals?
read article (free registration required) 

Roche Says Flexible Pricing Ready For Cancer, Not MS Drugs

(Reuters) Nov 7, 2016 - Roche has introduced flexible pricing for cancer drugs in about a dozen European countries, including Italy, Belgium, Hungary, Switzerland and Austria.
read article 

CryoVax(R) : Next Generation Immunotherapy for Metastatic Colorectal Cancer Begins USA Phase IIb Clinical Trial

(Yahoo! Finance) Nov 7, 2016 - Immunovative Therapies, Ltd., on behalf of it's subsidiary, ImmunoCare, Ltd., today announced the start of a Phase IIb study of CryoVax®, a next generation immunotherapy cancer vaccine product, for patients with chemotherapy-refractory (third line) metastatic colorectal cancer (mCRC).
read article 

New KEYTRUDA® (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting

(Merck) Nov 7, 2016 - First presentation of overall survival data in patients with advanced bladder (urothelial) cancer from Keynote-045 study.
read corporate press release 

Brain Tumor Characteristics Could Help Predict Survival In People Over 70

(Cancer Research UK/(NCRI) Nov 5, 2016 - Characteristics like seizures, location of the tumour, and pressure in the brain, give insight into length of survival and treatment options for brain tumour patients over the age of 70, according to new research presented at the National Cancer Research Institute's (NCRI) Cancer Conference in Liverpool.
read press release 

Weight Gain May Result In Increased Cancer Risk

( Nov 7, 2016 - Significant weight gain may lead to a sharp increase in the risk for developing obesity-related cancers, researchers in Britain say.
read article 

Gut Microbes Linked To Immunotherapy Response In Melanoma Patients

(Cancer Research UK/(NCRI) Nov 7, 2016 - Patients with malignant melanoma - whose disease has spread - are more likely to respond to immunotherapy treatment if they had greater diversity in their gut bacteria, according to new research presented at the National Cancer Research Institute's (NCRI) Cancer Conference in Liverpool.
read press release 

Study Calls Into Question Sunscreen in Melanoma Prevention

(Medscape Medical News) Nov 4, 2016 - Sunscreen likely provides protection against skin cancer in some high-risk groups, but it is probably not broadly effective, according to a study of children that used the appearance of new moles as a marker of melanoma risk.
read article (free registration required) 

Tumor Cells In Blood Samples Could Predict Prostate Cancer Spread

(Cancer Research UK/(NCRI) Nov 4, 2016 - Researchers have found a group of circulating tumour cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
read press release 

Do Second Opinions Matter in Prostate Cancer Care?

(Wiley) Nov 7, 2016 - A new analysis indicates that many men with prostate cancer obtain second opinions from urologists before starting treatment, but surprisingly, second opinions are not associated with changes in treatment choice or improvements in perceived quality of prostate cancer care.
read corporate press release 

Roche Advances Skin Cancer Trials As Part Of Combination Therapy Strategy

(Reuters) Nov 7, 2016 - Roche is pressing ahead with two skin cancer trials that combine its immunotherapy Tecentriq with other drugs after early data showed the treatments were well-tolerated and effective in a small number of patients, the company said Monday.
read article 

Bayer Applies For Regorafenib Authorization To Treat Liver Cancer

(Reuters) Nov 7, 2016 - German drugmaker Bayer on Monday said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer patients following successful clinical trials.
read article 

Bayer Submits Supplemental New Drug Application for Stivarga® (regorafenib) for Advanced Liver Cancer

(Bayer) Nov 7, 2016 - Bayer today announced that a supplemental New Drug Application (sNDA) for Stivarga® (regorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the second-line systemic treatment of patients with unresectable hepatocellular carcinoma (uHCC).
read corporate press release 

Exelixis Announces Presentation of Cobimetinib Combination Therapy Data at the Society for Melanoma Research 2016 Congress That Support Genentech’s Planned Phase 3 Pivotal Trials

(Yahoo! Finance) Nov 7, 2016 - Encouraging data in BRAF wild type advanced melanoma presented in advance of initiation of phase 3 pivotal trial next year; the third pivotal phase 3 trial of cobimetinib announced this year, reflecting robust late-stage development program.
read article 

The Ebola Virus Mutated to Better Infect Humans During the 2014 Outbreak

(Washington Post/Speaking of Science) Nov 3, 2016 - The Ebola virus mutated to more effectively infiltrate human cells during the West African outbreak that killed more than 11,300 people between 2013 and 2016.
read article (free registration required) 

What Clinical Trial Results? Now You Can See Who Isn’t Sharing Their Findings

(STAT/Pharmalot) Nov 3, 2016 - The results for nearly half of all clinical trials conducted by big drug makers during the last decade have not been published, and one company — Ranbaxy Laboratories — has not published findings for any of the nearly three dozen trials conducted in the past 10 years, according to a new online tool.
read article 

UK cHL Patients Get Early Access To Opdivo

(PharmaTimes [UK]) Nov 4, 2016 - UK patients with a certain form of blood cancer will get access to Bristol-Myers Squibb's immunotherapy Opdivo through the Early Access to Medicines Scheme (EAMS), ahead of its European license.
read article 

Federal Prosecutors Reportedly Plan Major Price Fixing Suit Against Drug Makers

(FORTUNE) Nov 3, 2016 - The bombshell news sent pharma stocks tumbling.
read article 

A Shortage of Oncologists

(New York Times/Well blog) Nov 3, 2016 - In the crucible of cancer treatment, the bonding of patients with physicians often makes the unendurable endurable.
read article 

Stand Up To Cancer Announces SU2C Catalyst™ Collaboration with Genentech to Support New Research on Cancer Treatments and Therapies

(AACR) Nov 3, 2016 - Stand Up To Cancer (SU2C) announced today an SU2C Catalyst™ collaboration with Genentech, a member of the Roche Group, that will help accelerate the development of new cancer treatments and combination therapies by giving awardees funding and access to a dozen of the company's medicines.
read press release